185 related articles for article (PubMed ID: 15930076)
21. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
22. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer JW
J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
[TBL] [Abstract][Full Text] [Related]
23. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.
Laugharne J; Waterreus AJ; Castle DJ; Dragovic M
Australas Psychiatry; 2016 Feb; 24(1):62-6. PubMed ID: 26635377
[TBL] [Abstract][Full Text] [Related]
24. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
Stein K
J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
[No Abstract] [Full Text] [Related]
25. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.
DelMonte MT; Bostwick JR; Bess JD; Dalack GW
J Clin Pharm Ther; 2012 Dec; 37(6):668-73. PubMed ID: 22845616
[TBL] [Abstract][Full Text] [Related]
26. [Antipsychotic prescription assessment in general practice: metabolic effects].
Gignoux-Froment F; de Montleau F; Saravane D; Verret C
Encephale; 2012 Dec; 38(6):453-9. PubMed ID: 23200610
[TBL] [Abstract][Full Text] [Related]
27. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.
Chang HH; Chou CH; Chen PS; Gean PW; Huang HC; Lin CY; Yang YK; Lu RB
J Affect Disord; 2009 Sep; 117(1-2):124-9. PubMed ID: 19193445
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.
Tanchoco CC; Cruz AJ; Duante CA; Litonjua AD
Asia Pac J Clin Nutr; 2003; 12(3):271-6. PubMed ID: 14505989
[TBL] [Abstract][Full Text] [Related]
30. Metabolic syndrome and its components in men.
Adriansjah H; Adam JM
Acta Med Indones; 2005; 37(2):66-70. PubMed ID: 20066787
[TBL] [Abstract][Full Text] [Related]
31. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN
Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566
[TBL] [Abstract][Full Text] [Related]
32. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.
Panagiotopoulos C; Ronsley R; Davidson J
Can J Psychiatry; 2009 Nov; 54(11):743-9. PubMed ID: 19961662
[TBL] [Abstract][Full Text] [Related]
33. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme.
Barnes TR; Paton C; Hancock E; Cavanagh MR; Taylor D; Lelliott P;
Acta Psychiatr Scand; 2008 Jul; 118(1):26-33. PubMed ID: 18582345
[TBL] [Abstract][Full Text] [Related]
34. Metabolic syndrome a widespread threatening condition; risk factors, diagnostic criteria, therapeutic options, prevention and controversies: an overview.
Amihăesei IC; Chelaru L
Rev Med Chir Soc Med Nat Iasi; 2014; 118(4):896-900. PubMed ID: 25581945
[TBL] [Abstract][Full Text] [Related]
35. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.
Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D
BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
[TBL] [Abstract][Full Text] [Related]
37. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
[TBL] [Abstract][Full Text] [Related]
38. After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health?
Martín Otaño L; Barbadillo Izquierdo L; Galdeano Mondragón A; Alonso Pinedo M; Querejeta Ayerdi I
Rev Psiquiatr Salud Ment; 2013; 6(1):26-32. PubMed ID: 23084806
[TBL] [Abstract][Full Text] [Related]
39. Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project.
Gil K; Radziłłowicz P; Zdrojewski T; Pakalska-Korcala A; Chwojnicki K; Piwoński J; Ignaszewska-Wyrzykowska A; Załuga L; Mielczarek M; Landowski J; Wyrzykowski B
Kardiol Pol; 2006 May; 64(5):464-9. PubMed ID: 16752328
[TBL] [Abstract][Full Text] [Related]
40. The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.
Basu R; Brar JS; Chengappa KN; John V; Parepally H; Gershon S; Schlicht P; Kupfer DJ
Bipolar Disord; 2004 Aug; 6(4):314-8. PubMed ID: 15225149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
